Chai Discovery, an AI‑driven biotech startup backed by OpenAI, announced a $130 million Series B financing round that lifts its valuation to $1.3 billion. The round was led by General Catalyst and Oak HC/FT, with participation from Menlo Ventures, OpenAI, Dimension, Thrive Capital, Neo, Yosemite venture fund, Lachy Groom, SV Angel, Glade Brook and Emerson Collective. The new capital brings the company’s total funding to over $225 million. Chai’s platform, now in its second generation (Chai 2), aims to accelerate drug discovery by using foundation models to design molecules and de‑novo antibodies, positioning the firm as a leading player in AI‑enabled biotech. Leer más →